A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Clinical trial NCT06295432 · RECRUITING

Trial details

NCT number: NCT06295432
Sponsor: Dizal Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2023-06-01
Primary completion: 2026-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.